All In Biotech

Drug Trial Radar · NCT07717840

A Study to Characterize the Safety and Immunogenicity of AZD6489 in Participants 60 Years of Age and Older (ARIES)

A Phase I/II, Randomized, Double-Blind, Active-Controlled Study to Characterize the Safety and Immunogenicity of AZD6489 in Adults 60 Years of Age and Older

Last checked: Nov 19, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 164 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

164

Actual

Start

Jul 8, 2026

Primary completion

Oct 1, 2026

Study completion Aug 19, 2027

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Jul 21, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This Phase I/II study is to characterize the safety and immunogenicity of 2 dose levels of AZD6489, an investigational RSV recombinant prefusion F protein VLP vaccine.

Conditions

  • RSV Respiratory Syncytial Virus

Interventions

  • AZD6489Biological

    Participants will receive AZD6489 as a single intramuscular injection.

  • Licensed RSV vaccine #1Biological

    Participants will receive licensed RSV vaccine #1 as a single intramuscular injection.

  • Licensed RSV vaccine #2Biological

    Participants will receive licensed RSV vaccine #2 as a single intramuscular injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of immediate unsolicited adverse events (AEs)Time frame: 30 minutes post-study intervention
  2. Incidence of injection site and systemic solicited adverse reactions (ARs)Time frame: Day 1 through 7 days post-study intervention
  3. Incidence of unsolicited adverse events (AEs)Time frame: Day 1 through 28 days post-study intervention
  4. Incidence of serious adverse events (SAEs)Time frame: Day 1 to Day 365
  5. Incidence of adverse events of special interest (AESIs)Time frame: Day 1 to Day 365
  6. Incidence of medically attended adverse events (MAAEs)Time frame: Day 1 to Day 365
  7. RSV A nAb responses to AZD6489Time frame: Day 29

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Long Beach, California

  • Research Site

    Rolling Hills Estates, California

  • Research Site

    Chicago, Illinois

  • Research Site

    Lenexa, Kansas

  • Research Site

    Kansas City, Missouri

  • Research Site

    Omaha, Nebraska

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.